Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?

World J Gastroenterol. 2014 Nov 28;20(44):16649-64. doi: 10.3748/wjg.v20.i44.16649.

Abstract

Obesity and its associated diseases are a worldwide epidemic disease. Usual weight loss cures - as diets, physical activity, behavior therapy and pharmacotherapy - have been continuously implemented but still have relatively poor long-term success and mainly scarce adherence. Bariatric surgery is to date the most effective long term treatment for morbid obesity and it has been proven to reduce obesity-related co-morbidities, among them nonalcoholic fatty liver disease, and mortality. This article summarizes such variations in gut hormones following the current metabolic surgery procedures. The profile of gut hormonal changes after bariatric surgery represents a strategy for the individuation of the most performing surgical procedures to achieve clinical results. About this topic, experts suggest that the individuation of the crosslink among the gut hormones, microbiome, the obesity and the bariatric surgery could lead to new and more specific therapeutic interventions for severe obesity and its co-morbidities, also non surgical.

Keywords: Bariatric surgery; Gut hormones; Microbiome; Nonalcoholic fatty liver disease; Obesity.

Publication types

  • Review

MeSH terms

  • Animals
  • Bariatric Surgery*
  • Comorbidity
  • Energy Metabolism
  • Feeding Behavior
  • Gastrointestinal Hormones / metabolism*
  • Gastrointestinal Tract / metabolism*
  • Homeostasis
  • Obesity / epidemiology
  • Obesity / metabolism
  • Obesity / physiopathology
  • Obesity / psychology
  • Obesity / surgery*
  • Risk Factors
  • Signal Transduction
  • Treatment Outcome

Substances

  • Gastrointestinal Hormones